RxDoctor Payments Data

Douglas Williams, MD

Neurology · Bristol, TNNPI 1528051208

Payments from drug & device makers

$19,358in general payments, 2019–2025

Across 1,003 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Novartis$1K
  • Lilly USA, LLC$953
  • Neurelis, Inc.$873
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$230%
  • Food & beverage$19,295100%
  • Education$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.86$2,394
AbbVie(2 entities)147$1,926
AstraZeneca(2 entities)47$1,021
Novartis55$1,008
Lilly USA, LLC53$953
Neurelis, Inc.26$873
Biogen43$739
Lundbeck LLC36$711
MDD US Operations, LLC36$675
Genentech USA, Inc.28$543
Acadia Pharmaceuticals Inc37$535
TG Therapeutics, Inc.13$448
Eisai Inc.23$446
Teva Pharmaceuticals USA, Inc.28$430
Jazz Pharmaceuticals Inc.14$399
Argenx US, Inc.19$387
Amgen(2 entities)18$387
Sunovion Pharmaceuticals Inc.23$330
Pfizer23$310
Kyowa Kirin, Inc.14$306
Bristol Myers Squibb15$299
Neurocrine Biosciences, Inc.18$297
SK Life Science, Inc.11$284
Sanofi13$282
Supernus Pharmaceuticals, Inc.12$221
Mallinckrodt Hospital Products Inc.8$181
Avanir Pharmaceuticals, Inc.10$168
Upsher-smith Laboratories LLC10$167
Merz Pharmaceuticals, LLC7$166
Greenwich Biosciences, Inc.6$160
Johnson & Johnson10$157
Amneal Pharmaceuticals LLC8$147
Otsuka America Pharmaceutical, Inc.7$145
CSL Behring6$139
Sumitomo Pharma America, Inc.8$134
Adamas Pharmaceuticals, Inc.6$124
Corium, LLC6$123
Ipsen Biopharmaceuticals, Inc5$109
Biohaven Pharmaceuticals, Inc.6$94
Catalyst Pharmaceuticals, Inc.4$92
Impel Pharmaceuticals Inc.4$89
Biohaven Pharmaceutical Holding Company Ltd.5$88
Takeda Pharmaceuticals U.S.A., Inc.6$80
GE HealthCare2$70
EMD Serono, Inc.4$64
Avion Pharmaceuticals3$61
Mallinckrodt Enterprises LLC3$59
Arbor Pharmaceuticals, Inc.4$58
Aucta Pharmaceuticals, Inc.2$51
Aprecia Pharmaceuticals, LLC3$51
Harmony Biosciences LLC2$47
E.r. Squibb & Sons, L.L.C.3$42
Assertio Therapeutics, Inc.3$41
Vanda Pharmaceuticals Inc.2$40
Scilex Pharmaceuticals Inc.2$37
Banner Life Sciences, LLC2$32
Averitas Pharma Inc.1$29
Livanova USA, Inc.2$26
Impel Pharmaceuticals LLC1$23
Grifols USA, LLC1$20

How this compares

$19,358 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$41,397
Medicare patients
281
Services billed
567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate41$219,374
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$175,754
Kesimpta PenOfatumumab16$136,931
TecfideraDimethyl Fumarate13$120,643
Emgality PenGalcanezumab-Gnlm162$118,282
Gamunex-CImmune Globul G/Gly/Iga Avg 4626$100,250
BotoxOnabotulinumtoxina54$66,344
Dimethyl Fumarate28$50,904
Nurtec OdtRimegepant Sulfate35$47,141
BriviactBrivaracetam28$39,405
QuliptaAtogepant29$35,676
UbrelvyUbrogepant17$18,755
Lacosamide164$16,264
VimpatLacosamide12$10,944
Carbidopa-LevodopaCarbidopa/Levodopa426$7,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$535$219,37441 claims
CSL BehringPrivigen$139$175,75412 claims
AbbVieBotox, Qulipta, Ubrelvy$1,926$120,775100 claims
BiogenTecfidera$739$120,64313 claims
Grifols USA, LLCGamunex-C$20$100,25026 claims
UCB, Inc.Briviact, Vimpat$2,394$50,34940 claims
PfizerNurtec Odt, Dilantin$310$50,06950 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$147$11,442129 claims
Upsher-smith Laboratories LLCTopiramate$167$1,778173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.

Other neurology in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →